Adapted physical activity programs for the prevention and treatment of musculoskeletal pain induced by aromatase inhibitors in non-metastatic breast cancer patient: a scoping review.
1Health, Systemic, Process (P2S), UR4129, University Claude Bernard, Lyon 1, University of Lyon, 69008 Lyon, France; Service de Gynécologie-Obstétrique, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France. Electronic address: nathalie.piazzon@chu-lyon.fr.
2Service de Gynécologie-Obstétrique, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France; LabTAU, INSERM U 1032, University Claude Bernard Lyon 1, Lyon, France.
3Health, Systemic, Process (P2S), UR4129, University Claude Bernard, Lyon 1, University of Lyon, 69008 Lyon, France; CIC EC 1408 INSERM Saint-Etienne, Saint-Etienne cedex 2, France; PRESAGE Institut, University Jean Monnet, University of Lyon, Saint-Etienne, France.
4Health, Systemic, Process (P2S), UR4129, University Claude Bernard, Lyon 1, University of Lyon, 69008 Lyon, France.
Background: Aromatase inhibitor is associated with a high incidence of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in postmenopausal women with hormone-sensitive breast cancer.
Objective: This scoping review aims to identify available information regarding the frameworks, models, or strategies of adapted physical activity (APA) programs implemented for the prevention and management of AIMSS.
Methods: Search was realized by two independent reviewers in six databases following PRISMA-ScR guidelines. Data of included articles were extracted, and risk of bias analyzed.
Results: Finally, 14 were included. No study has examined APA in the prevention of AIMSS. There is no solid evidence supporting the impact of APA on the management of AIMSS. However, evidence suggests that an APA program can reduce the worst joint pain and improve the quality of life.
Conclusion: Future research will enlighten clinical practices with the development of personalized APA programs in hormone-sensitive breast cancer.
Keywords: Aromatase Inhibitor-Associated Musculoskeletal Syndrome; Breast neoplasm; aromatase inhibitor; musculoskeletal pain; physical activity; tertiary prevention.
